Inflammatory cytokines and their potential role in Sjogren's syndrome risk: insights from a mendelian randomization study.

IF 2 4区 医学 Q3 RHEUMATOLOGY
Wenbin Shi, Yuli Xu, Anan Zhang, Xiqun Jia, Shuhua Liu, Ziyang Hu
{"title":"Inflammatory cytokines and their potential role in Sjogren's syndrome risk: insights from a mendelian randomization study.","authors":"Wenbin Shi, Yuli Xu, Anan Zhang, Xiqun Jia, Shuhua Liu, Ziyang Hu","doi":"10.1186/s42358-024-00354-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR).</p><p><strong>Materials and methods: </strong>Leveraging GWAS summary data of inflammatory cytokines and SS, we executed the first two-sample MR analysis. Genetic variants from prior GWASs associated with circulating inflammatory cytokines served as instrumental variables (IVs). Data regarding cytokines were analyzed using the Olink Target-96 Inflammation panel, synthesizing data from 14,824 participants. GWAS summary statistics for SS were procured from the UK Biobank, focusing on samples of European ancestry. To discern the causal relationship between inflammatory cytokines and SS, several MR methodologies, including inverse variance weighted (IVW) and MR-Egger regression, were applied.</p><p><strong>Results: </strong>After rigorous IV quality control, 91 cytokines were incorporated into the MR analysis. The IVW analysis identified 8 cytokines with a positive association to SS: Axin-1 (OR 2.56, 95% CI 1.07-6.10), T-cell surface glycoprotein CD5 (OR 1.81, 95% CI 1.08-3.02), CUDP1 (OR 1.61, 95% CI 1.00-2.58), CXCL10 (OR 1.92, 95% CI 1.25-2.95), IL-4 (OR 2.18, 95% CI 1.22-3.91), IL-7 (OR 2.35, 95% CI 1.27-4.33), MCP-2 (OR 1.27, 95% CI 1.05-1.54), and TNFRSF9 (OR 1.83, 95% CI 1.03-3.24), suggesting their potential in increasing SS risk.</p><p><strong>Conclusion: </strong>Our study conducted through MR, identified various inflammatory cytokines associated with SS risk, validating some previous research results and offering some new potential biomarkers for SS. However, these findings necessitate further research for validation and exploration of their precise role in the onset and progression of SS.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s42358-024-00354-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR).

Materials and methods: Leveraging GWAS summary data of inflammatory cytokines and SS, we executed the first two-sample MR analysis. Genetic variants from prior GWASs associated with circulating inflammatory cytokines served as instrumental variables (IVs). Data regarding cytokines were analyzed using the Olink Target-96 Inflammation panel, synthesizing data from 14,824 participants. GWAS summary statistics for SS were procured from the UK Biobank, focusing on samples of European ancestry. To discern the causal relationship between inflammatory cytokines and SS, several MR methodologies, including inverse variance weighted (IVW) and MR-Egger regression, were applied.

Results: After rigorous IV quality control, 91 cytokines were incorporated into the MR analysis. The IVW analysis identified 8 cytokines with a positive association to SS: Axin-1 (OR 2.56, 95% CI 1.07-6.10), T-cell surface glycoprotein CD5 (OR 1.81, 95% CI 1.08-3.02), CUDP1 (OR 1.61, 95% CI 1.00-2.58), CXCL10 (OR 1.92, 95% CI 1.25-2.95), IL-4 (OR 2.18, 95% CI 1.22-3.91), IL-7 (OR 2.35, 95% CI 1.27-4.33), MCP-2 (OR 1.27, 95% CI 1.05-1.54), and TNFRSF9 (OR 1.83, 95% CI 1.03-3.24), suggesting their potential in increasing SS risk.

Conclusion: Our study conducted through MR, identified various inflammatory cytokines associated with SS risk, validating some previous research results and offering some new potential biomarkers for SS. However, these findings necessitate further research for validation and exploration of their precise role in the onset and progression of SS.

炎性细胞因子及其在 Sjogren's 综合征风险中的潜在作用:一项孟德尔随机研究的启示。
目的:本研究旨在探讨炎性细胞因子对斯尤金综合征(SS)的因果影响,并利用孟德尔随机化(MR)方法确定斯尤金综合征临床管理的潜在生物标志物:利用炎性细胞因子和SS的GWAS汇总数据,我们首次进行了双样本MR分析。先前的全球基因组研究中与循环炎症细胞因子相关的基因变异作为工具变量(IV)。有关细胞因子的数据使用 Olink Target-96 Inflammation 面板进行分析,综合了来自 14,824 名参与者的数据。SS的GWAS汇总统计数据来自英国生物库,侧重于欧洲血统的样本。为了确定炎性细胞因子与 SS 之间的因果关系,研究人员采用了几种 MR 方法,包括反方差加权(IVW)和 MR-Egger 回归:经过严格的 IV 质量控制,91 种细胞因子被纳入 MR 分析。IVW 分析确定了 8 种与 SS 呈正相关的细胞因子:Axin-1(OR 2.56,95% CI 1.07-6.10)、T 细胞表面糖蛋白 CD5(OR 1.81,95% CI 1.08-3.02)、CUDP1(OR 1.61,95% CI 1.00-2.58)、CXCL10(OR 1.92,95% CI 1.25-2.95)、IL-4(OR 2.18,95% CI 1.22-3.91)、IL-7(OR 2.35,95% CI 1.27-4.33)、MCP-2(OR 1.27,95% CI 1.05-1.54)和 TNFRSF9(OR 1.83,95% CI 1.03-3.24),表明它们可能增加 SS 风险:我们的研究通过磁共振成像发现了与 SS 风险相关的各种炎症细胞因子,验证了之前的一些研究成果,并为 SS 提供了一些新的潜在生物标志物。然而,这些发现还需要进一步研究,以验证和探索它们在 SS 发病和进展中的确切作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Rheumatology
Advances in Rheumatology Medicine-Rheumatology
CiteScore
4.00
自引率
4.30%
发文量
41
审稿时长
53 weeks
期刊介绍: Formerly named Revista Brasileira de Reumatologia, the journal is celebrating its 60th year of publication. Advances in Rheumatology is an international, open access journal publishing pre-clinical, translational and clinical studies on all aspects of paediatric and adult rheumatic diseases, including degenerative, inflammatory and autoimmune conditions. The journal is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines and letters arising from published material.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信